Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology.

It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.

The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.